Efficacy of Cell-Free and Concentrated Ascites Reinfusion Therapy for Palliative Care in a Patient with Malignant Pleural Mesothelioma: A Case Report.

We report the case of malignant ascites in a patient with malignant pleural mesothelioma (MPM) whose symptoms were relieved by CART. A 59-year-old Japanese male with MPM who had undergone pleural decortication had pleural and peritoneal recurrence. His general status deteriorated as he developed massive ascites due to peritoneal metastases. With the initiation of CART, he recovered well enough to receive cisplatin-based systemic chemotherapy. Repeated use of CART contributed to the maintenance of his good general condition and enabled him to undergo successive systemic chemotherapy, which might have lengthened his life. This is the first report that demonstrates the efficacy of CART for palliative care in a patient with MPM. Our experience indicates that CART should be considered as a treatment option to control refractory malignant ascites regardless of the type of cancer. PMID: 29142184 [PubMed - in process]
Source: Journal of Nippon Medical School - Category: Universities & Medical Training Authors: Tags: J Nippon Med Sch Source Type: research

Related Links:

CONCLUSIONS: The pPCI strongly differs from the sPCI for patients undergoing CRS for peritoneal disease and may provide a more accurate evaluation of the peritoneal disease extent. Further studies are needed to determine its prognostic value compared with sPCI, and consensus guidelines are needed for calculating it. PMID: 32040698 [PubMed - as supplied by publisher]
Source: Ann Oncol - Category: Cancer & Oncology Authors: Tags: Ann Surg Oncol Source Type: research
This study aimed to report long-term outcomes for low-grade PMP and MM treated by laparoscopic approach.MethodsFrom a prospectively maintained CRS-HIPEC database, all patients who underwent laparoscopic CRS-HIPEC with curative intent were analyzed. Selection criteria for laparoscopic approach were low-grade PMP or MM, with pathological confirmation prior to CRS-HIPEC, ASA 2, age  
Source: Surgical Endoscopy - Category: Surgery Source Type: research
Publication date: November 2019Source: Human Pathology: Case Reports, Volume 18Author(s): Yuri Noda, Yuko Nakanishi, Kumi Masuda, Masaru YamasakiAbstractSarcomatoid mesothelioma (SM) is the rarest subtype of malignant mesothelioma (MM) with the poorest prognosis. Due to its aggressive nature, early diagnosis and treatment are required for SM, resulting in they significantly improve patient survival. Until now, effusion cytology using ancillary techniques has aided in the early diagnosis of MM, and the cytological findings of the epithelioid component of MM have been well described. However, there has been no detailed cytom...
Source: Human Pathology: Case Reports - Category: Pathology Source Type: research
Publication date: Available online 14 November 2019Source: European Journal of Surgical OncologyAuthor(s): Aditi Bhatt, Yutaka Yonemura, Sanket Mehta, Nazim Benzerdjeb, Praveen Kammar, Loma Parikh, Mita Y. Shah, Sakina Shaikh BHMS, Aruna Prabhu, Suniti Mishra, Snita Sinukumar, Vahan Kepenekian, Naoual Bakrin, Guillaume Passot, Olivier GlehenAbstractBackgroundThe aim was to study the patterns of target region (greater omentum, lesser omentum, falciform and umbilical round ligament) involvement in patients undergoing cytoreductive surgery (CRS) from various primary tumors, factors affecting involvement and implications on su...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Abstract Adifferential diagnosis of ascites is always challenging for physicians. Peritoneal tuberculosis is particularly difficult to distinguish from peritoneal carcinomatosis because of the similarities in clinical manifestations and laboratory results. Although the definitive diagnostic method for ascites is to take a biopsy of the involved tissues through laparoscopy or laparotomy, there are many limitations in performing biopsies in clinical practice. For this reason, physicians have attempted to find surrogate markers that can substitute for a biopsy as a confirmative diagnostic method for ascites. CA 125, ...
Source: Korean J Gastroenter... - Category: Gastroenterology Authors: Tags: Korean J Gastroenterol Source Type: research
Patients with peritoneal mesothelioma undergoing a second cytoreductive surgery had a median survival of 92 months, according to a recent study at St. George Hospital and the University of South Wales in Sydney, Australia. That same group of patients also had a five-year survival rate of 71.8%, further illustrating the progress being made in treating the peritoneal subtype of this rare and aggressive cancer. The Journal of Surgical Oncology published the study in July 2019. The single-center study detailed the survival benefits of cytoreduction and perioperative intraperitoneal chemotherapy in colorectal, ovarian, appendic...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Abstract The multimodal treatment of limited peritoneal metastases may improve prognosis in selected patients (pseudomyxoma peritonei, malignant peritoneal mesothelioma, colorectal, gastric and ovarian cancer) provided complete cytoreduction can be performed. Additive intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) is often performed. If the treatment is undertaken in experienced (and certified) centres, associated mortality is low. Intrapleural hyperthermic chemoperfusion (HITOC) can be performed in patients with pleural malignancies, mainly for malignant pleural mesothelioma or metastases from a...
Source: Zentralblatt fur Chirurgie - Category: Surgery Authors: Tags: Zentralbl Chir Source Type: research
ConclusionsOxaliplatin-based PIPAC appears to be a safe treatment that offers good symptom control and promising survival for patients with advanced peritoneal disease.
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Dr. James Cusack at Massachusetts General Hospital has begun using a novel imaging system for patients with peritoneal mesothelioma that could better identify tumor cells during surgery, reducing the chance of recurrence. Cusack, an associate professor of surgery at the Harvard University Medical School, is also studying the molecular imaging technology with select cases of appendiceal, ovarian and gastrointestinal cancers. The single-center clinical trial, which started April 3, aims to determine safety and efficacy of the procedure for peritoneum metastases, according to Cusack. The Lumicell System already has been studi...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conclusions: We found different patterns in mortality in the main asbestos-related tumors.
Source: Journal of Occupational and Environmental Medicine - Category: Occupational Health Tags: ORIGINAL ARTICLES Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Gastroenterology | Japan Health | Mesothelioma | Palliative | Palliative Care | Peritoneal Cancer | Study | Universities & Medical Training